Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.55 USD
333.76 K USD
0.00 USD
6.38 M
About PharmaCyte Biotech, Inc.
Sector
CEO
Joshua Nathaniel Silverman
Headquarters
Las Vegas
Website
Founded
1996
FIGI
BBG000BBVY94
PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Las Vegas, NV.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of PMCB is 1.56 USD — it hasn't changed in the past 24 hours. Watch PharmaCyte Biotech, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange PharmaCyte Biotech, Inc. stocks are traded under the ticker PMCB.
PMCB stock has fallen by −3.03% compared to the previous week, the month change is a −4.76% fall, over the last year PharmaCyte Biotech, Inc. has showed a −30.67% decrease.
PMCB reached its all-time high on Oct 8, 2003 with the price of 1,249.99 USD, and its all-time low was 1.39 USD and was reached on Aug 27, 2024. View more price dynamics on PMCB chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
PMCB stock is 3.24% volatile and has beta coefficient of 1.25. Track PharmaCyte Biotech, Inc. stock price on the chart and check out the list of the most volatile stocks — is PharmaCyte Biotech, Inc. there?
Yes, you can track PharmaCyte Biotech, Inc. financials in yearly and quarterly reports right on TradingView.
PharmaCyte Biotech, Inc. is going to release the next earnings report on Mar 18, 2025. Keep track of upcoming events with our Earnings Calendar.
PMCB net income for the last quarter is −1.47 M USD, while the quarter before that showed 23.42 M USD of net income which accounts for −106.27% change. Track more PharmaCyte Biotech, Inc. financial stats to get the full picture.
No, PMCB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 27, 2024, the company has 2.00 employees. See our rating of the largest employees — is PharmaCyte Biotech, Inc. on this list?
Like other stocks, PMCB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PharmaCyte Biotech, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PharmaCyte Biotech, Inc. technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PharmaCyte Biotech, Inc. stock shows the sell signal. See more of PharmaCyte Biotech, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.